Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.

Zannad F, Stough WG, Lipicky RJ, Tamargo J, Bakris GL, Borer JS, Alonso GarcĂ­a Mde L, Hadjadj S, Koenig W, Kupfer S, McCullough PA, Mosenzon O, Pocock S, Scheen AJ, Sourij H, Van der Schueren B, Stahre C, White WB, Calvo G.

Eur Heart J Cardiovasc Pharmacother. 2016 Jul;2(3):200-5. doi: 10.1093/ehjcvp/pvw007. Review.

PMID:
27418973
2.

Is randomization to placebo safe? Risk in placebo-controlled angina trials: angina risk meta-analysis.

Glasser SP, Willard J, Defelice A, Lawrence J, Hung J, Obot E, Girton J, Targum S, Throckmorton D, Mangano D, Lipicky RJ.

Cardiology. 2011;120(3):174-81. doi: 10.1159/000335522.

3.

Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humans.

Cushing DJ, Adams MP, Cooper WD, Zhang B, Lipicky RJ, Kowey PR.

Am J Cardiol. 2009 Oct 15;104(8):1152-7. doi: 10.1016/j.amjcard.2009.06.010.

PMID:
19801040
4.

The hypotensive effect of intravenous amiodarone is sustained throughout the maintenance infusion period.

Cushing DJ, Cooper WD, Gralinski MR, Lipicky RJ.

Clin Exp Pharmacol Physiol. 2010 Mar;37(3):358-61. doi: 10.1111/j.1440-1681.2009.05303.x.

PMID:
19793107
5.

Comparison of the cardiac electrophysiology and general toxicology of two formulations of intravenous amiodarone in dogs.

Cushing DJ, Cooper WD, Gralinski MR, Lipicky RJ, Kudenchuk PJ, Kowey PR.

Cardiovasc Toxicol. 2009 Sep;9(3):126-33. doi: 10.1007/s12012-009-9044-4.

PMID:
19554478
6.

Bioequivalence of 2 intravenous amiodarone formulations in healthy participants.

Cushing DJ, Adams MP, Cooper WD, Kowey PR, Lipicky RJ.

J Clin Pharmacol. 2009 Apr;49(4):407-15. doi: 10.1177/0091270008330156.

PMID:
19246726
7.

PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects.

Cushing DJ, Kowey PR, Cooper WD, Massey BW, Gralinski MR, Lipicky RJ.

Eur J Pharmacol. 2009 Apr 1;607(1-3):167-72. doi: 10.1016/j.ejphar.2009.02.009.

PMID:
19232340
8.

Effect of dronedarone on cardiovascular events in atrial fibrillation.

Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA Investigators..

N Engl J Med. 2009 Feb 12;360(7):668-78. doi: 10.1056/NEJMoa0803778. Erratum in: N Engl J Med. 2009 Jun 4;360(23):2487. N Engl J Med. 2011 Apr 14;364(15):1481.

10.

The risks associated with short-term placebo-controlled antihypertensive clinical trials: a descriptive meta-analysis.

DeFelice A, Willard J, Lawrence J, Hung J, Gordon MA, Karkowsky A, Targum S, Throckmorton DC, Girton J, Stertz B, Glasser SP, Lipicky RJ.

J Hum Hypertens. 2008 Oct;22(10):659-68. doi: 10.1038/jhh.2008.51.

PMID:
18528409
11.

Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk.

Brass EP, Lewis RJ, Lipicky R, Murphy J, Hiatt WR.

Clin Pharmacol Ther. 2006 Mar;79(3):165-72. Review. No abstract available.

PMID:
16513441
12.

Drug-induced torsades de pointes and implications for drug development.

Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, Ruskin JN, Lipicky RJ, Cantilena LR; Independent Academic Task Force..

J Cardiovasc Electrophysiol. 2004 Apr;15(4):475-95. Review.

13.

Task Force I: methodological aspects of blood pressure measurement.

O'Brien E, van Montfrans G, Palatini P, Tochikubo O, Staessen J, Shirasaki O, Lipicky R, Myers M.

Blood Press Monit. 2001 Dec;6(6):313-5. Review.

PMID:
12055408
14.

Assessment of antihypertensive activity in the regulatory setting.

Myers MG, Lipicky RJ.

Blood Press Monit. 2001 Dec;6(6):309-12.

PMID:
12055407
15.

Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.

Fleming T, Borer J, Lipicky R, Armstrong PW.

Circulation. 2001 Oct 30;104(18):E9039. No abstract available.

16.

Report from the 93rd Cardiovascular and Renal Drugs Advisory Committee Meeting, August 9-10, 2001.

Fleming T, Lindenfeld J, Lipicky R, Armstrong P.

Circulation. 2001 Oct 9;104(15):1742. No abstract available.

17.

An FDA perspective on antiarrhythmic drugs in phase II trials.

Lipicky R.

Am Heart J. 2000 Apr;139(4):S197-9. No abstract available.

PMID:
10740131
18.

Myonecrosis after revascularization procedures.

Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA, Kleiman NS, Mahaffey KW, Topol EJ, Pepine CJ, Lipicky RJ, Granger CB, Harrington RA, Tardiff BE, Crenshaw BS, Bauman RP, Zuckerman BD, Chaitman BR, Bittl JA, Ohman EM.

J Am Coll Cardiol. 1998 Feb;31(2):241-51. Review.

19.

On the trough-to-peak ratio of drug effect in antihypertensive trials.

Fenichel RR, Lipicky RJ.

Am J Hypertens. 1996 Oct;9(10 Pt 2):105S-107S; discussion 108S-109S. Review.

PMID:
8896672
20.

Defining the regulatory role of ambulatory blood pressure monitoring. ABPM Steering Committee.

Lipicky RJ, Stockbridge N.

Ann N Y Acad Sci. 1996 Aug 15;783:304-307.

PMID:
8853652

Supplemental Content

Loading ...
Support Center